Compare NOAH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | EVO |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | China | Germany |
| Employees | N/A | 4766 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.2M | 821.2M |
| IPO Year | 2010 | N/A |
| Metric | NOAH | EVO |
|---|---|---|
| Price | $11.29 | $2.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.75 | $7.00 |
| AVG Volume (30 Days) | ★ 126.0K | 107.5K |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | $7.13 |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.67 | $2.31 |
| 52 Week High | $12.84 | $4.80 |
| Indicator | NOAH | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 36.37 |
| Support Level | $11.11 | $2.31 |
| Resistance Level | $11.34 | $3.78 |
| Average True Range (ATR) | 0.31 | 0.08 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 35.19 | 24.30 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.